J. Hudson

发表

Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.

Alexander G. Dossetter, S. Steinbacher, P. Macfaul, 2012, Journal of medicinal chemistry.

Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.

Alexander G. Dossetter, S. Steinbacher, P. Macfaul, 2012, Bioorganic & medicinal chemistry letters.

(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.

Alexander G. Dossetter, S. Steinbacher, P. Macfaul, 2012, Journal of medicinal chemistry.

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.

Hayley S. Brown, D. Laber, James S. Scott, 2014, Journal of medicinal chemistry.

The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.

J. Bower, J. G. Cumming, Michael James, 2012, Bioorganic & medicinal chemistry letters.

Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.

Andrew G. Leach, Hayley S. Brown, D. Laber, 2012, Journal of medicinal chemistry.

Facile synthesis of 3-alkoxyindoles via rhodium(II)-catalysed diazoindole O–H insertion reactions

J. Kettle, Shaun M. Fillery, A. Faull, 2000 .

Acidity of hydrocarbons. XXVIII. Hydrogen isotope exchange of polyfluorobenzenes with sodium methoxide in methanol

A. Streitwieser, J. Hudson, F. Mares, 1968 .

Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.

John G Cumming, Jeremy N Burrows, J. G. Cumming, 2005, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma.

Nichola L. Davies, A. Ferguson, L. Drew, 2017, Journal of medicinal chemistry.

Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both monotherapy and combination therapy in models of non-small cell lung cancer (NSCLC).

J. Breed, M. Anderton, Lyman J. L. Feron, 2019, Journal of medicinal chemistry.

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point.

J. Debreczeni, Lyman J. L. Feron, Michael Tonge, 2017, Journal of medicinal chemistry.

A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.

G. R. Brown, A. Foubister, J. Hudson, 1995, Journal of medicinal chemistry.

Improved synthetic routes to the novel thromboxane receptor antagonist ICI 192605: activity of synthetic 1,3‐dioxane intermediates

G. R. Brown, J. Hudson, Alan J. Foubister, 1990, The Journal of pharmacy and pharmacology.

Optimisation of aqueous solubility in a series of G protein coupled receptor 119 (GPR119) agonists

Andrew G. Leach, Hayley S. Brown, James S. Scott, 2013 .

Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors

Philip A. MacFaul, Graeme R. Robb, Andrew G. Leach, 2013 .

Oxadiazole isomers: all bioisosteres are not created equal

Andrew G. Leach, James S. Scott, P. Macfaul, 2012 .

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.

Andrew G. Leach, Hayley S. Brown, D. Laber, 2014, Journal of medicinal chemistry.